S&P 500   4,288.67 (+0.01%)
DOW   33,447.31 (-0.18%)
QQQ   357.55 (-0.20%)
AAPL   171.12 (-0.05%)
MSFT   315.68 (-0.02%)
META   300.70 (+0.16%)
GOOGL   130.31 (-0.42%)
AMZN   126.90 (-0.17%)
TSLA   240.58 (-3.85%)
NVDA   438.16 (+0.73%)
NIO   8.92 (-1.33%)
BABA   86.75 (+0.01%)
AMD   102.65 (-0.17%)
T   15.01 (-0.07%)
F   12.34 (-0.64%)
MU   68.03 (+0.00%)
CGC   0.78 (-0.97%)
GE   110.00 (-0.50%)
DIS   80.82 (-0.28%)
AMC   8.05 (+0.75%)
PFE   33.13 (-0.12%)
PYPL   58.65 (+0.33%)
NFLX   377.00 (-0.16%)
S&P 500   4,288.67 (+0.01%)
DOW   33,447.31 (-0.18%)
QQQ   357.55 (-0.20%)
AAPL   171.12 (-0.05%)
MSFT   315.68 (-0.02%)
META   300.70 (+0.16%)
GOOGL   130.31 (-0.42%)
AMZN   126.90 (-0.17%)
TSLA   240.58 (-3.85%)
NVDA   438.16 (+0.73%)
NIO   8.92 (-1.33%)
BABA   86.75 (+0.01%)
AMD   102.65 (-0.17%)
T   15.01 (-0.07%)
F   12.34 (-0.64%)
MU   68.03 (+0.00%)
CGC   0.78 (-0.97%)
GE   110.00 (-0.50%)
DIS   80.82 (-0.28%)
AMC   8.05 (+0.75%)
PFE   33.13 (-0.12%)
PYPL   58.65 (+0.33%)
NFLX   377.00 (-0.16%)
S&P 500   4,288.67 (+0.01%)
DOW   33,447.31 (-0.18%)
QQQ   357.55 (-0.20%)
AAPL   171.12 (-0.05%)
MSFT   315.68 (-0.02%)
META   300.70 (+0.16%)
GOOGL   130.31 (-0.42%)
AMZN   126.90 (-0.17%)
TSLA   240.58 (-3.85%)
NVDA   438.16 (+0.73%)
NIO   8.92 (-1.33%)
BABA   86.75 (+0.01%)
AMD   102.65 (-0.17%)
T   15.01 (-0.07%)
F   12.34 (-0.64%)
MU   68.03 (+0.00%)
CGC   0.78 (-0.97%)
GE   110.00 (-0.50%)
DIS   80.82 (-0.28%)
AMC   8.05 (+0.75%)
PFE   33.13 (-0.12%)
PYPL   58.65 (+0.33%)
NFLX   377.00 (-0.16%)
S&P 500   4,288.67 (+0.01%)
DOW   33,447.31 (-0.18%)
QQQ   357.55 (-0.20%)
AAPL   171.12 (-0.05%)
MSFT   315.68 (-0.02%)
META   300.70 (+0.16%)
GOOGL   130.31 (-0.42%)
AMZN   126.90 (-0.17%)
TSLA   240.58 (-3.85%)
NVDA   438.16 (+0.73%)
NIO   8.92 (-1.33%)
BABA   86.75 (+0.01%)
AMD   102.65 (-0.17%)
T   15.01 (-0.07%)
F   12.34 (-0.64%)
MU   68.03 (+0.00%)
CGC   0.78 (-0.97%)
GE   110.00 (-0.50%)
DIS   80.82 (-0.28%)
AMC   8.05 (+0.75%)
PFE   33.13 (-0.12%)
PYPL   58.65 (+0.33%)
NFLX   377.00 (-0.16%)
NASDAQ:DICE

DICE Therapeutics (DICE) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$47.55
▼
$47.55
50-Day Range
$46.62
▼
$47.55
52-Week Range
$15.08
▼
$47.90
Volume
N/A
Average Volume
1.03 million shs
Market Capitalization
$2.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$62.40
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

DICE Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.46 Rating Score
Upside/​Downside
31.2% Upside
$62.40 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.57) to ($3.44) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.21 out of 5 stars

Medical Sector

942nd out of 969 stocks

Biotechnology Industry

10th out of 13 stocks

See Top Rated MarketRank™ Stocks Here

DICE stock logo

About DICE Therapeutics (NASDAQ:DICE) Stock

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.


DICE Stock News Headlines

September 29, 2023 | msn.com
Is Eli Lilly Stock A Buy Now That It Has Topped A Profit-Taking Zone?
September 11, 2023 | markets.businessinsider.com
Wells Fargo Sticks to Their Hold Rating for Incyte (INCY)
October 2, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
August 9, 2023 | markets.businessinsider.com
What 9 Analyst Ratings Have To Say About DICE Therapeutics
August 9, 2023 | finanznachrichten.de
Eli Lilly and Company: Lilly Completes Acquisition of DICE Therapeutics
August 9, 2023 | msn.com
HC Wainwright & Co. Reiterates DICE Therapeutics (DICE) Neutral Recommendation
August 9, 2023 | finance.yahoo.com
Lilly Completes Acquisition of DICE Therapeutics
August 8, 2023 | finanznachrichten.de
Eli Lilly and Company: Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements
October 2, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
August 8, 2023 | markets.businessinsider.com
Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements
July 25, 2023 | markets.businessinsider.com
Lilly Extends Tender Offer To Acquire DICE
July 25, 2023 | finance.yahoo.com
Lilly Announces Extension of Tender Offer to Acquire DICE
July 12, 2023 | msn.com
Drugmakers’ deal making will plow ahead despite antitrust scrutiny, analysts say
July 6, 2023 | msn.com
DICE Therapeutics (DICE) Price Target Decreased by 19.70% to 50.21
June 27, 2023 | finance.yahoo.com
Mergers Are Down, but These 2 Sectors Are Booming
June 26, 2023 | benzinga.com
Short Volatility Alert: Dice Therapeutics
June 26, 2023 | msn.com
Needham Downgrades DICE Therapeutics (DICE)
June 26, 2023 | benzinga.com
Needham Downgrades DICE Therapeutics to Hold
June 21, 2023 | markets.businessinsider.com
Dice Therapeutics (DICE) Receives a New Rating from a Top Analyst
June 21, 2023 | msn.com
Cantor Fitzgerald Downgrades DICE Therapeutics (DICE)
June 21, 2023 | msn.com
Canaccord Genuity Downgrades DICE Therapeutics (DICE)
June 20, 2023 | msn.com
Analyst Expectations for DICE Therapeutics's Future
June 20, 2023 | wsj.com
The Lilly-Dice Biotech Buyout Deals Short Sellers Another Blow
June 20, 2023 | fool.com
Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know
June 20, 2023 | markets.businessinsider.com
Why DICE Therapeutics Stock Is Soaring Tuesday
June 20, 2023 | finance.yahoo.com
Lilly Decides to Roll the Dice: My Plan for the Stock Now
June 20, 2023 | finance.yahoo.com
PayPal-KKR deal, Alibaba shares fall, Eli Lilly-Dice Therapeutics deal: Trending tickers
See More Headlines
Receive DICE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DICE Company Calendar

Last Earnings
8/08/2023
Today
10/02/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DICE
CUSIP
N/A
CIK
1645569
Web
www.dicemolecules.com
Phone
650-566-1420
Fax
N/A
Employees
71
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$62.40
High Stock Price Forecast
$77.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+31.2%
Consensus Rating
Hold
Rating Score (0-4)
2.46
Research Coverage
13 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-83,890,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-22.01%
Return on Assets
-20.79%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
25.88
Quick Ratio
32.44

Sales & Book Value

Annual Sales
$1.13 million
Price / Sales
2,008.50
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.86 per share
Price / Book
4.38

Miscellaneous

Outstanding Shares
47,731,000
Free Float
45,392,000
Market Cap
$2.27 billion
Optionable
Not Optionable
Beta
1.03
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. J. Kevin Judice Ph.D. (Age 59)
    Founder, CEO & Director
    Comp: $840k
  • Mr. Scott Robertson
    Chief Bus. & Financial Officer
  • Dr. Timothy Lu M.D. (Age 48)
    Ph.D., Chief Medical Officer
    Comp: $700k
  • Dr. John R. Jacobsen Ph.D. (Age 54)
    Chief Scientific Officer
  • Ms. Mary Riley J.D.
    Gen. Counsel
  • Mr. Venkat Thalladi Ph.D.
    Sr. VP of CMC
  • Mr. Paul Fatheree
    Sr. VP of Medicinal Chemistry

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













DICE Stock - Frequently Asked Questions

Should I buy or sell DICE Therapeutics stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DICE Therapeutics in the last twelve months. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DICE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DICE, but not buy additional shares or sell existing shares.
View DICE analyst ratings or view top-rated stocks.

What is DICE Therapeutics' stock price forecast for 2023?

13 equities research analysts have issued twelve-month price objectives for DICE Therapeutics' shares. Their DICE share price forecasts range from $48.00 to $77.00. On average, they anticipate the company's share price to reach $62.40 in the next twelve months. This suggests a possible upside of 31.2% from the stock's current price.
View analysts price targets for DICE or view top-rated stocks among Wall Street analysts.

When is DICE Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our DICE earnings forecast.

How were DICE Therapeutics' earnings last quarter?

DICE Therapeutics, Inc. (NASDAQ:DICE) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by $0.09.

What ETFs hold DICE Therapeutics' stock?

ETFs with the largest weight of DICE Therapeutics (NASDAQ:DICE) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), AltShares Merger Arbitrage ETF (ARB), First Trust Merger Arbitrage ETF (MARB), ProShares Merger ETF (MRGR), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and AltShares Event-Driven ET (EVNT).

When did DICE Therapeutics IPO?

(DICE) raised $160 million in an IPO on Wednesday, September 15th 2021. The company issued 10,000,000 shares at $15.00-$17.00 per share.

What is DICE Therapeutics' stock symbol?

DICE Therapeutics trades on the NASDAQ under the ticker symbol "DICE."

What is DICE Therapeutics' stock price today?

One share of DICE stock can currently be purchased for approximately $47.55.

How much money does DICE Therapeutics make?

DICE Therapeutics (NASDAQ:DICE) has a market capitalization of $2.27 billion and generates $1.13 million in revenue each year. The company earns $-83,890,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis.

How can I contact DICE Therapeutics?

DICE Therapeutics' mailing address is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.dicemolecules.com. The company can be reached via phone at 650-566-1420 or via email at investors@dicetx.com.

This page (NASDAQ:DICE) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -